Smith Bryan E. 4
4 · Urovant Sciences Ltd. · Filed Feb 21, 2020
Insider Transaction Report
Form 4
Smith Bryan E.
GC of Urovant Sciences,Inc.
Transactions
- Exercise/Conversion
Common Shares
2020-02-19$6.88/sh+50,000$344,000→ 100,000 total - Tax Payment
Common Shares
2020-02-19$13.08/sh−34,835$455,642→ 65,165 total - Other
Common Shares
2020-02-19$13.08/sh−15,165$198,358→ 50,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-02-19+50,000→ 20,000 totalExercise: $6.88Exp: 2029-01-06→ Common Shares (50,000 underlying)
Footnotes (3)
- [F1]Represents 26,300 shares surrendered to the Issuer in satisfaction of payment of exercise price and 8,535 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options.
- [F2]Represents the sale of 15,165 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction.
- [F3]All of the shares underlying this option are vested and exercisable as of the date hereof.